SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Eris Lifesciences - Quaterly Results

13 Nov 2025 Evaluate
The Sales for the quarter ended September 2025 of Rs. 6505.00 millions rose by 49.01% from Rs. 4365.60 millions.The Net Profit of the company vaulted to 432.28% to Rs. 1495.70  millions from Rs. 281.00 millions in the previous quarter.OP of the company witnessed a marginal growth to 3204.70 millions from 1484.40 millions in the same quarter last year.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202509 202409 % Var 202509 202409 % Var 202503 202403 % Var
Sales 6505.00 4365.60 49.01 12291.40 8932.50 37.60 16977.50 14867.10 14.20
Other Income 235.90 58.10 306.02 462.70 109.70 321.79 355.10 348.30 1.95
PBIDT 3204.70 1484.40 115.89 5594.70 2769.80 101.99 5220.60 4886.50 6.84
Interest 465.00 562.60 -17.35 916.40 1124.30 -18.49 2202.40 574.20 283.56
PBDT 2739.70 921.80 197.21 4678.30 1645.50 184.31 3018.20 4312.30 -30.01
Depreciation 393.00 461.60 -14.86 769.00 917.10 -16.15 1817.70 1023.90 77.53
PBT 2346.70 460.20 409.93 3909.30 728.40 436.70 1200.50 3288.40 -63.49
TAX 851.00 179.20 374.89 1413.70 277.00 410.36 426.60 291.20 46.50
Deferred Tax 441.90 91.40 383.48 732.90 142.30 415.04 206.80 -285.20 -172.51
PAT 1495.70 281.00 432.28 2495.60 451.40 452.86 773.90 2997.20 -74.18
Equity 136.20 136.10 0.07 136.20 136.10 0.07 136.20 136.00 0.15
PBIDTM(%) 49.27 34.00 44.89 45.52 31.01 46.79 30.75 32.87 -6.44

Eris Lifesciences Share Price

1432.95 -13.55 (-0.94%)
20-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1668.00
Dr. Reddys Lab 1232.25
Cipla 1228.90
Zydus Lifesciences 936.35
Lupin 2328.60
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×